

ONE SAMPLE FOR COMPLETE INFORMATION ABOUT THE HEALTH OF YOUR CERVIX - **"LBC"**

THE

- FROM A SINGLE SAMPLING PERFORMED DURING YOUR REGULAR GYNECOLOGICAL EXAMINATION, IT IS POSSIBLE TO INVESTIGATE:
 - HPV test the presence of a high-risk type of human papillomavirus (HPV)
 - "Liquid based" cytology microscopic inspection of epithelial cells
 - Imunocytochemistry special markers of serious cellular changes
 - Methylation test test of preservation of protective cellular antitumor mechanisms
 - Sexually transmitted infections identification of sexually transmitted bacteria and viruses
 - Composition of microbial vaginal flora finding the cause of vaginal discomfort

All examinations are performed by Biopticka laboratorio s.r.o., the largest European laboratory accredited for cervical cancer screening

ASK YOUR GYNECOLOGIST

Cervical cancer screening

- Every year in the Czech Republic, approximately 900 women are newly diagnosed with cervical cancer (CRC) and almost 400 women die from it
- KDČ is caused by long-term infection with human papillomavirus (HPV) and it does not develop until several years after infection, so it does not only affect sexually active women
- More than 80% of the population will be infected with the HPV virus during their lifetime, vaccination against HPV significantly reduces the risk of developing KDČ
- KDČ screening is a preventive program that can be used to detect the disease in its early, pre-cancerous stages
- KDČ screening is part of a regular checkup with your gynecologist
- Early detection of pre-cancerous changes means almost 100% certainty of a complete cure

The following examinations can be performed from a smear performed with the LBC ThinPrep PAP TEST method

- Cytology assessment of pre-tumor or tumor changes in cells under a microscope
 - By collecting cells in a liquid medium ("liquid based" cytology), the quality of the collected cells is preserved
 - Cells are examined microscopically in a thin layer (ThinPrep)
 - A unique software system examines each cell in the smear and the evaluating physician determines the severity of cellular changes

• HPV DNA/ HPV RNA test* - identification of the causative agent of the disease - HPV

- HPV DNA test identifies the presence of so-called high-risk HPV types and at the same time determines whether aggressive HPV types are present 16, 18
- HPV mRNA test Aptima identifies clinically serious infections with high-risk HPV types and specifically determines the activity of types 16, 18 and 45
- HPV genotyping will determine the specific HPV type, including the HPV types that cause genital warts
- Imunocytochemistry* p16/Ki67 marker to determine the severity of pre-tumors cellular changes
- Methylation test (OiaSure)* test for preservation of the "anti-cancer" brake
 - Intended for women with a positive HPV test or abnormal cytology
 - The test determines the severity of damage to cellular antitumor mechanisms
 - It will help in deciding whether to undergo surgery

Sexually transmitted infections* - identification of the cause of gynecological problems

- "STI7" test detection of the presence of the most common sexually transmitted pathogens (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycop/asma genitalium, Mycoplasm1bllllfill --- hominis, Ureap/asma urealyticum and Ureap/asma parvum, Trichomonas vaginalis)
- "Genital ulcer" test detection of the presence of the causative agents of genital ulcers
- Composition of microbial vaginal flora*
 - "Vaginitis" test detection of the presence and amount of bacteria and yeast that cause vaginal discomfort (discharge, bacterial vaginosis)

* Ask your gynecologist for test prices

Bioptická laboratoř s.r.o., Mikulášské nám. 4, 326 00 Plzeň tel.: +420 373 035 500, biopticka@biopticka.cz, www.biopticka.cz